Benzinga | Jul 28, 2020 11:28AM EDT

Barclays Maintains Overweight on CRISPR Therapeutics, Raises Price Target to $102

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and raises the price target from $65 to $102.